Dose Of China’S Vaccine Diplomacy

2021-02-27   |   by CusiGO

This week, Hungary began vaccinating its population with the first dose of 550000 doses of covid vaccine from Sinopharm, a Chinese pharmaceutical company. A plane landed in Buenos Aires with another 900000 people. In Manila, 600000 doses of Chinese vaccine are expected to arrive this weekend, the first batch donated by the Chinese government to Manila. “If we insist on using the west, we will still wait for them,” stressed Harry Roque, a spokesman for the Philippine President.

Before Russia had sputnik-5 (or, to a lesser extent, India, thanks to its covaxin), China had become a great alternative to providing vaccines to many developing countries, which, in most cases, had difficulty in obtaining medicines for economic or logistical reasons. According to Beijing’s Ministry of foreign affairs, the countries that found the first case of influenza have agreed to provide sera to 80 countries in Southeast Asia, Latin America, Africa or Eastern Europe: 27 of them will buy sera, and 53 resource poor countries will receive donations. According to data from Duke University, China has committed more than 500 million doses, more than 300 million doses from Moscow or 210 million doses from the covax mechanism, It is supported by the World Health Organization (who) to ensure equitable access to vaccines for all countries (Beijing has committed 10 million doses to the device).

The supply of formula milk powder in China helps to alleviate the urgent global demand for vaccines. But it also provides a powerful opportunity to improve its pharmaceutical capabilities. It helps to build up the image of a responsible power – just as he tried to do in the first wave of the influenza pandemic through his “mask diplomacy” among many criticisms, Different from western countries, western countries provide assistance through covax, focusing on ensuring that their own population can obtain immune serum.

In terms of ensuring equitable access to vaccines, China has become a global leader in “making use of its drugs”, filling the gap between developed and developing countries. ‘it will certainly enhance their image in these countries and project soft power,’ said Yanzhong Huang of the U.S. International Relations Council in a video conference organized by the Stimson center, a think-tank. His “vaccine diplomacy” also enabled him to “fill the gap left by the US leadership.”. “The withdrawal of the United States from the global leadership has created opportunities for China to fill this gap,” the expert said

For Beijing, the development of vaccines has become a top priority since the start of the pandemic. “The success of our formula clinical trials with intellectual property rights reflects the progress of science and technology in our country, the image and responsibility of China as a big country and, most importantly, its contribution to mankind,” said General Chen Wei. Responsible for developing vaccines in army laboratories. Chinese President Xi Jinping announced in May that these traditional Chinese medicines will become a “global public good.”.

If by January 2020, China has the first batch of serum samples, then by summer, China has obtained an emergency use license, and has more than a dozen kinds of formula milk powder in different progress states, then it will start to vaccinate the most advanced front-line workers, from soldiers to doctors or transport workers. On December 31, China Pharmacopoeia approved the first general public authorization of formula milk powder in China Pharmacopoeia, with the validity period of 79%. One month later, the validity period of China Pharmacopoeia was 50.6%. By early February, it had vaccinated 22 million people, nearly 3% of its population.

This week he has made more progress. Two other vaccines have been approved for general use: the second version of Sinopharm (72.5% effectiveness) and the vaccine developed by cansino in collaboration with the military (65.28%). While major cities are speeding up dose management, it is also speeding up the delivery of goods abroad: in the past seven days, goods have been received, inter Alia, from Colombia, Mexico, Chile and Uruguay, Senegal, Egypt and Algeria, Sierra Leone, Thailand and Singapore. According to the National Vaccine Manufacturers Association, by the end of this year, 2 billion doses of vaccine will be produced, and by the end of 2022, the production capacity will reach 4 billion doses.

For many countries, China’s vaccines – except cansino’s, which use inactivated viruses – are more suitable for their needs. They don’t need to be stored at the low temperatures of Pfizer or Hyundai’s competitors, while the cannino version only needs one dose. In addition, some agreements signed with other countries, such as the United Arab Emirates or Indonesia, provide that these countries can produce their own sera under license. This will help to meet the strong demand while supporting the ambition of these countries to become pharmaceutical production centres in their respective regions.

Beijing denies any geopolitical interests in its strategy. “China will not turn the coved vaccine into any political weapon or diplomatic tool, and oppose any politicization of vaccine development,” the official Xinhua news agency said in an editorial. The Xi Jinping administration claimed that, as the global times, a Communist Party of China, said on Thursday, it was merely “addressing the vaccine shortage in the absence of the West.”.

This view has been echoed in recipient countries. In addition to the statement made by Philippine spokesman Jacques Roque, Senegalese President Macky Sall also stressed that there is a lack of vaccines injected through covax and that his country cannot wait to explain its investment in Chinese vaccines, In the debates from the southern cone to the South China Sea. In an interview with the financial times last week, French President Emmanuel macron urged western countries to provide more vaccines to developing countries.

“This is an unprecedented acceleration of global inequality and politically unsustainable as it paves the way for a war that affects vaccines,” said head of state Gaul. “You can see China’s strategy and you can see Russia’s strategy.”

It’s not just that prestige as a great power is at stake. Vaccines are also a business, and very profitable: the price in Indonesia is about $20 per dose, and the country has ordered 125 million doses of the first two approved Chinese formulas, “which means $2.5 billion… Chinese companies will invest a lot of money,” said the source International relations.

Just as robotics or artificial intelligence do in promoting Chinese technology, the formulation against covid may promote the development of its pharmaceutical industry, which so far lags behind competitors such as India, a geopolitical rival and a strong country in the industry. According to akriti Vasudeva, an expert at the Stimson center, it is no accident that New Delhi provides serum to countries where “China maintains or aspires to have significant influence” (such as Sri Lanka, Myanmar or Cambodia).

The initial welcome was not grudging. As Robert Blake, the former US ambassador to Indonesia, explained, “China does not have the same record (in drug sales) as other countries. It is a new competitor. Moreover, it is less transparent than others in publishing its data or submitting it to others for review. ”

The relative inefficiency of Chinese formula is also a factor in the fight against these vaccines. In addition to the individual risk of not being fully immunized, it may become more difficult or require more doses to realize the dream of sheep immunization, and extend social distance and public health protection measures for a longer time. On Friday, health workers at Manila general hospital protested against plans to vaccinate with Sinovac formula and demanded a “safer” vaccine.

But black recalled that despite these shortcomings, the reality was that “countries are trying to get as many doses as possible.”. “They can’t afford options, they need to be vaccinated as soon as possible.”